RNA-transfected mature autologous dendritic cells

An investigational autologous dendritic cell-based cancer vaccine developed by Duke University for the treatment of metastatic melanoma. The vaccine is produced by collecting a patient's peripheral blood mononuclear cells via leukapheresis, differentiating monocytes into dendritic cells using GM-CSF and IL-4, and maturing them with a cytokine cocktail. These mature dendritic cells are then transfected via electroporation with messenger RNA (mRNA) encoding four melanoma tumor-associated antigens: MART-1, tyrosinase, gp100, and MAGE-3. When administered intranodally, these dendritic cells present the processed antigens to the host's immune system, specifically targeting and activating anti-tumor T-cell responses against melanoma cells expressing these proteins. In clinical trials, this vaccine has been evaluated both alone and in combination with other immune modulators, such as dendritic cells expressing GITR-L or anti-CTLA-4 antibodies, to enhance the anti-tumor immune response.

Other names

RNA-transfected mature autologous dendritic cells-Duke University-metastatic melanomamRNA-transfected autologous dendritic cell vaccineDuke University melanoma DC vaccineMART-1/Tyrosinase/gp100/MAGE-3 mRNA-transfected dendritic cells